Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-040"

Predicate	Value (sorted: none)
lpv:spokenAs	member; Temporary Committee on Climate Change (2007-05-10--2009-02-04)3
lpv:spokenAs	member; ENVI (2007-01-31--2009-07-13)3
lpv:spokenAs	member; EPP-ED (2007-02-15--2009-07-13)3
lpv:spokenAs	unknown; Union pour un Mouvement Populaire (2004-07-20--2009-07-13)3
lpv:spokenAs	member; Delegation to the Euro-Mediterranean Parliamentary Assembly (2004-09-15--2009-07-13)3
lpv:spokenAs	member; Delegation for relations with Australia and New Zealand (2007-03-15--2009-07-13)3
lpv:spokenAs	substitute; ITRE (2007-01-31--2009-07-13)3
lpv:translated text	". − Mr President, firstly I would like to thank my fellow Members who have spoken in support of the report that I presented. I would remind those who, unfortunately, are no longer here but who expressed some concerns, that this really does constitute an improvement, harmonisation and simplification of procedures. However, the simplification of procedures does not mean lowering quality or having fewer controls. It represents lower costs for industry and, above all, for SMEs, which is essential. Lower costs and saving time: in other words, European patients will finally have quicker access to medicines. I sincerely hope, moreover, that we will conclude at first reading. We have done everything possible so that an agreement can be reached, and naturally I would like once more to thank the Commission for its help, as well as the Council. With regard to counterfeiting, we were delighted, Mr Verheugen, to hear the information you gave concerning the text which you will present to us, as soon as possible I hope, since you are aware that we are anxious to see it. Counterfeiting, as my fellow Members said, is a crime and we cannot wait when it comes to crime. We know that the vast majority of sales of medicines on the Internet concern counterfeit medicines which are therefore dangerous for citizens’ health. Well, you spoke of active ingredients and the controls which we must apply to active ingredients, including when they are manufactured, when they are produced in third countries, and not in the European Union. Yes, this is essential. We will be there to help you because we are going to have to work on traceability, penalties for offenders and safety of the distribution chain. It is important for patients to have 100% confidence in the medicines they are prescribed: it must not be possible to open or repackage these medicines. This is what I wanted to say on behalf of all of my fellow Members. Mr Verheugen, I would like you to know that when leaving here today, you will have Parliament’s full support, and it is essential to convince the College of Commissioners that we must not waste any more time but at last take action against the counterfeiting of medicines."@en1
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Variations to the terms of marketing authorisations for medicinal products - Counterfeiting of medicinal products (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20081022.2.3-040"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-0412
lpv:speaker	lp:Françoise Grossetête2
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph